ISDA: 4PNZ

Deposition Date 2014-02-22

Release Date 2014-04-09

Last Version Date 2024-10-16

Entry Detail

PDB ID:

4PNZ

Keywords:

HYDROLASE/HYDROLASE INHIBITOR

Title:

Human dipeptidyl peptidase IV/CD26 in complex with the long-acting inhibitor Omarigliptin (MK-3102)

Biological Source:

Source Organism(s):

Homo sapiens (Taxon ID: 9606)

Expression System(s):

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.90 Å

R-Value Free:

0.19

R-Value Work:

0.16

R-Value Observed:

0.16

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Dipeptidyl peptidase 4
Gene (Uniprot):DPP4
Mutagens:S39T
Chain IDs:A, B
Chain Length:728
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P27487 Pfam ID:PF00930, PF00326 EC:3.4.14.5

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
ASN	A	ASN	GLYCOSYLATION SITE

Ligand Molecules

2VH

NAG

Primary Citation

Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes.

Biftu, T, Sinha-Roy, R, Chen, P, Qian, X, Feng, D, Kuethe, J.T, Scapin, G, Gao, Y.D, Yan, Y, Krueger, D, Bak, A, Eiermann, G, He, J, Cox, J, Hicks, J, Lyons, K, He, H, Salituro, G, Tong, S, Patel, S, Doss, G, Petrov, A, Wu, J, Xu, S.S, Sewall, C, Zhang, X, Zhang, B, Thornberry, N.A, Weber, A.E.Show

J.Med.Chem. 57 3205 3212 (2014)

PMID: 24660890 DOI: 10.1021/jm401992e

Abstact

In our effort to discover DPP-4 inhibitors with added benefits over currently commercially available DPP-4 inhibitors, MK-3102 (omarigliptin), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profile amenable for once-weekly human dosing and selected as a clinical development candidate. This manuscript summarizes the mechanism of action, scientific rationale, medicinal chemistry, pharmacokinetic properties, and human efficacy data for omarigliptin, which is currently in phase 3 clinical development.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form